Osteopontin is a prognostic biomarker in non-small cell lung cancer

[1]  Liquid Biopsies.  Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.

[2]  G. Mælandsmo,et al.  Osteopontin is a prognostic biomarker in non-small cell lung cancer , 2013, BMC Cancer.

[3]  Jianmin Li,et al.  Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis , 2013, Journal of experimental & clinical cancer research : CR.

[4]  F. Tanaka,et al.  Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. , 2013, Clinical lung cancer.

[5]  Q. Ye,et al.  Osteopontin promoter polymorphisms at locus ‐443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma , 2013, Hepatology.

[6]  G. Mælandsmo,et al.  Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer , 2012, BMC Cancer.

[7]  J. Minna,et al.  Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion , 2012, Molecular Cancer Therapeutics.

[8]  Jian Feng,et al.  FoxQ1 Overexpression Influences Poor Prognosis in Non-Small Cell Lung Cancer, Associates with the Phenomenon of EMT , 2012, PloS one.

[9]  G. Banfi,et al.  Stability of osteopontin in plasma and serum , 2012, Clinical chemistry and laboratory medicine.

[10]  M. Sonobe,et al.  Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. , 2012, Lung cancer.

[11]  E. Kraynov,et al.  Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[12]  Bai Zhao,et al.  Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[13]  G. Weber,et al.  Osteopontin is a marker for cancer aggressiveness and patient survival , 2010, British Journal of Cancer.

[14]  G. Kundu,et al.  Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells , 2010, Molecular Cancer.

[15]  Elena B. Pasquale,et al.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.

[16]  H. Pass,et al.  Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Kjetil Boye,et al.  S100A4 and metastasis: a small actor playing many roles. , 2010, The American journal of pathology.

[18]  P. Mack,et al.  Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004 , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  S. Kageyama,et al.  Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. , 2009, Anticancer research.

[20]  Lukas M Orre,et al.  Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. , 2009, Lung cancer.

[21]  G. Kundt,et al.  The functional −443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c‐Myb transcription factor , 2009, Molecular carcinogenesis.

[22]  M. Shinohara,et al.  Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells , 2008, Proceedings of the National Academy of Sciences.

[23]  Y. Chang,et al.  Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. , 2007, Lung cancer.

[24]  S. Ishikawa,et al.  Differential expression of S100A2 and S100A4 in lung adenocarcinomas: Clinicopathological significance, relationship to p53 and identification of their target genes , 2005, Cancer science.

[25]  G. Fontanini,et al.  Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[26]  G. Fontanini,et al.  Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer , 2005, British Journal of Cancer.

[27]  D. Lin,et al.  Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[28]  R. Ravazzolo,et al.  Polymorphisms in the osteopontin promoter affect its transcriptional activity. , 2004, Physiological genomics.

[29]  S. Mikalsen,et al.  Immunofluorometric Assay for the Metastasis-Related Protein S100A4: Release of S100A4 from Normal Blood Cells Prohibits the Use of S100A4 as a Tumor Marker in Plasma and Serum , 2004, Tumor Biology.

[30]  A. Hölscher,et al.  Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[31]  K. Giercksky,et al.  Direct identification of all oncogenic mutants in KRAS exon 1 by cycling temperature capillary electrophoresis , 2003, Electrophoresis.

[32]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[33]  C. Heizmann,et al.  Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. , 2000, International journal of oncology.

[34]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[35]  A. Scheel.  [The Norwegian radium hospital]. , 1951, Nordisk Medicin.